> Details

Watanabe, Toshiyasu; Shinozaki, Eiji; Kijima, Sho; Ohhara, Yoshihito; Kuboki, Yasutoshi; Takagi, Koichi; Ozaka, Masato; Ogura, Mariko; Kikuchi, Yoshinori; Suenaga, Mitsukuni; Chin, Keisho; Matsusaka, Satoshi; Koike, Junichi; Funahashi, Kimihiko; Urita, Yoshihisa; Mizunuma, Nobuyuki; Hatake, Kiyohiko; Kaneko, Hironori; Sugimoto, Motonobu

Does panitumumab have a clinical benefit in cetuximab-refractory KRAS wild-type metastatic colorectal cancer?

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Does panitumumab have a clinical benefit in cetuximab-refractory KRAS wild-type metastatic colorectal cancer?
  • Contributor: Watanabe, Toshiyasu; Shinozaki, Eiji; Kijima, Sho; Ohhara, Yoshihito; Kuboki, Yasutoshi; Takagi, Koichi; Ozaka, Masato; Ogura, Mariko; Kikuchi, Yoshinori; Suenaga, Mitsukuni; Chin, Keisho; Matsusaka, Satoshi; Koike, Junichi; Funahashi, Kimihiko; Urita, Yoshihisa; Mizunuma, Nobuyuki; Hatake, Kiyohiko; Kaneko, Hironori; Sugimoto, Motonobu
  • imprint: American Society of Clinical Oncology (ASCO), 2012
  • Published in: Journal of Clinical Oncology
  • Language: English
  • DOI: 10.1200/jco.2012.30.4_suppl.654
  • ISSN: 0732-183X; 1527-7755
  • Keywords: Cancer Research ; Oncology
  • Origination:
  • Footnote:
  • Description: <jats:p> 654 </jats:p><jats:p> Background: Panitumumab and cetuximab can be used in metastatic colorectal cancer (mCRC) and these drugs are IgG2 fully human and IgG1 chimeric (mouse/human) monoclonal antibody against the epidermal growth hactor receptor (EGFR) respectively. The efficacy of panitumumab as a salvage chemotherapy after cetuximab-based chemotherapy failure is not clarified. </jats:p><jats:p> Methods: This study aimed to evaluate the panitumumab efficacy to KRAS wild-type mCRC patients who failed cetuximab-based chemotherapy. Response, progression-free survival (PFS) and serum tumor marker level (CEA and CA19-9), were assesed. We studied response by days from last cetuximab-based chemotherapy to panitumumab induction (C-P days). </jats:p><jats:p> Results: 22 patients (11 men, 11 women, median age 54 years m4 0-78 n) were enrolled. All of thease patients were cetuximab-based chemotherapy refractory KRAS wild-type mCRC. After progression, they received panitumumab monotherapy (6 mg/kg every 2 weeks).The best response was SD 10/22 (45.5%), PD 11/22 (50%) and NE 1/22 (4.5%). Overall median PFS was 90 days (13 to 182). The patients C-P days less than 30 days were 15 patients(5:SD, 10:PD). The patients more than 79 days were 7 patient(5:SD, 1:PD, 1:NE). Serum tumor marker level was decreased more than 50% patients. </jats:p><jats:p> Conclusions: This study suggested that it might be limited as possibility of clinical benefit with panitumumab administration after cetuximab failure. </jats:p>
  • Access State: Open Access